Drug
Insulin Glargine Lantus
Insulin Glargine Lantus: highest development phase Post-Market, developed by Sanofi. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Sanofi
Trials
| Drug | Phase | Indication |
|---|---|---|
| Insulin Glargine (HOE901) [Lantus] NCT00949442 | Post-Market | Diabetes Mellitus, Type 2 |
Latest
No recent events.
Follow Insulin Glargine Lantus on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.